EUHASS is a pharmacovigilance program to monitor the safety of treatments for people with inherited bleeding disorders in Europe. Haemophilia treatment centres report adverse events directly to the EUHASS website and regular surveillance reports are produced.
Participating Haemophilia treatment centres report adverse events directly to the EUHASS web application. (Restricted Access)
EUHASS maintains a publicly accessible list of all clotting factor concentrates used in Europe. The directory is searchable and gives the product characteristics.
This secure SharePoint system is to aid the EUHASS Project Administration Team.
(Restricted Access)
EUHASS maintains a database of all the Haemophilia Centres in Europe with details of how they can be accessed by patients.
| Event Type | Reported |
| Allergic/Other Acute | 182 |
| Transfusion Transmitted Infections | |
| Inhibitors – first occurrence | 486 |
| Inhibitors – recurrence | 53 |
| Thrombosis | 244 |
| Malignancy | 616 |
| Deaths | 1096 |
| Total Adverse Events (Since October 2008) | 2677 |